CNCR vs. LFSC

Last updated Apr 3, 2026

Compare and contrast key facts about Loncar Cancer Immunotherapy ETF (CNCR) and F/m Emerald Life Sciences Innovation ETF (LFSC).

CNCR and LFSC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024.

Performance

CNCR vs. LFSC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and F/m Emerald Life Sciences Innovation ETF (LFSC). The values are adjusted to include any dividend payments, if applicable.

CNCR vs. LFSC - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
LFSC F/m Emerald Life Sciences Innovation ETF	-1.18%

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

LFSC

• 1D: -0.19%
• 1M: -3.88%
• YTD: -4.62%
• 6M: 18.37%
• 1Y: 59.47%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. LFSC - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than LFSC's 0.54% expense ratio.

CNCR

Loncar Cancer Immunotherapy ETF

LFSC

F/m Emerald Life Sciences Innovation ETF

Return for Risk

CNCR vs. LFSC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LFSC

LFSC Risk / Return Rank: 87
LFSC Sharpe Ratio Rank: 90
LFSC Sortino Ratio Rank: 91
LFSC Omega Ratio Rank: 84
LFSC Calmar Ratio Rank: 90
LFSC Martin Ratio Rank: 78

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. LFSC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and F/m Emerald Life Sciences Innovation ETF (LFSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	LFSC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.06	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.94	—

Dividends

CNCR vs. LFSC - Dividend Comparison

Neither CNCR nor LFSC has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CNCR vs. LFSC - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum LFSC drawdown of -29.74%. Use the drawdown chart below to compare losses from any high point for CNCR and LFSC.

Drawdown Indicators

	CNCR	LFSC	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-29.74%	+29.74%
Max Drawdown (1Y) Largest decline over 1 year	—	-16.25%	—
Current Drawdown Current decline from peak	0.00%	-11.25%	+11.25%
Average Drawdown Average peak-to-trough decline	0.00%	-8.26%	+8.26%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	5.84%	—

Volatility

Volatility by Period

	CNCR	LFSC	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	10.08%	—
Volatility (6M) Calculated over the trailing 6-month period	—	19.95%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	29.12%	-29.12%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	29.27%	-29.27%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	29.27%	-29.27%